|
|
|
Insider
Information: |
Champsi Farah |
Relationship: |
Director |
City: |
San Francisco |
State: |
CA |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
9 |
|
Direct
Shares |
27,970,466 |
|
Indirect Shares
|
2,373,959 |
|
|
Direct
Value |
$194,968,747 |
|
|
Indirect Value
|
$8,435,524 |
|
|
Total
Shares |
30,344,425 |
|
|
Total
Value |
$203,404,271 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
0
|
0
|
Stock
price went up :
|
0
|
0
|
Stock
price went down : |
0
|
0
|
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
Percentage
Gain/Loss : |
0.0%
|
0.0%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Renovis Inc |
RNVS |
10% Owner |
2005-08-08 |
45,087 |
2005-08-08 |
24,499 |
Premium* |
|
Viracta Therapeutics Ord Shs |
VIRX |
Former 10% Owner |
2010-06-30 |
15,487,876 |
2010-06-30 |
381,683 |
Premium* |
|
Corcept Therapeutics Inc |
CORT |
10% Owner |
2009-10-16 |
5,484,063 |
2009-10-16 |
180,204 |
Premium* |
|
Chimerix Inc |
CMRX |
Director |
2013-04-16 |
0 |
2013-10-23 |
1,714,330 |
Premium* |
|
Portola Pharmaceuticals Inc |
PTLA |
Director |
2013-05-28 |
0 |
2013-05-28 |
27,507 |
Premium* |
|
Scynexis Inc |
SCYX |
10% Owner |
2014-05-07 |
1,240,575 |
2014-05-07 |
45,736 |
Premium* |
|
Zs Pharma, Inc. |
ZSPH |
10% Owner |
2014-06-23 |
3,230,090 |
2014-06-23 |
0 |
Premium* |
|
Immune Design Corp. |
IMDZ |
10% Owner |
2014-07-29 |
2,482,775 |
2014-07-29 |
0 |
Premium* |
|
Kite Pharma, Inc. |
KITE |
Director |
2017-10-03 |
0 |
2017-06-16 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 1 of 1
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
VIRX |
Viracta Therapeutics Ord ... |
Former 10% Owner |
|
2010-06-30 |
4 |
A |
$0.00 |
$0 |
D/D |
4,577,280 |
15,487,876 |
0 |
- |
|
VIRX |
Viracta Therapeutics Ord ... |
Former 10% Owner |
|
2010-06-30 |
4 |
B |
$0.28 |
$3,000,414 |
D/D |
10,910,596 |
10,910,596 |
2.44 |
- |
|
CORT |
Corcept Therapeutics Inc |
10% Owner |
|
2009-10-16 |
4 |
B |
$1.38 |
$465,398 |
D/D |
337,245 |
5,484,063 |
2.45 |
- |
|
ZSPH |
Zs Pharma, Inc. |
10% Owner |
|
2014-06-23 |
4 |
B |
$18.00 |
$3,600,000 |
D/D |
200,000 |
3,230,090 |
2.45 |
- |
|
ZSPH |
Zs Pharma, Inc. |
10% Owner |
|
2014-06-23 |
4 |
A |
$0.00 |
$0 |
D/D |
3,030,090 |
3,030,090 |
0 |
- |
|
IMDZ |
Immune Design Corp. |
10% Owner |
|
2014-07-29 |
4 |
B |
$12.00 |
$3,594,708 |
D/D |
299,559 |
2,482,775 |
2.45 |
- |
|
IMDZ |
Immune Design Corp. |
10% Owner |
|
2014-07-29 |
4 |
A |
$0.00 |
$0 |
D/D |
2,183,216 |
2,183,216 |
0 |
- |
|
CMRX |
Chimerix Inc |
Director |
|
2013-04-16 |
4 |
A |
$0.00 |
$0 |
I/I |
2,066,185 |
2,161,829 |
0 |
- |
|
VIRX |
Viracta Therapeutics Ord ... |
10% Owner |
|
2009-04-03 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
2,044,750 |
|
- |
|
KITE |
Kite Pharma, Inc. |
Director |
|
2015-06-30 |
4 |
S |
$61.22 |
$41,403,803 |
I/I |
(664,102) |
1,761,957 |
0 |
- |
|
CMRX |
Chimerix Inc |
Director |
|
2013-10-23 |
4 |
S |
$15.51 |
$6,940,709 |
I/I |
(447,499) |
1,714,330 |
0 |
- |
|
SCYX |
Scynexis Inc |
10% Owner |
|
2014-05-07 |
4 |
B |
$10.00 |
$8,680,660 |
D/D |
868,066 |
1,240,575 |
2.45 |
- |
|
VIRX |
Viracta Therapeutics Ord ... |
Former 10% Owner |
|
2010-06-30 |
4 |
A |
$0.00 |
$0 |
I/I |
420,190 |
381,683 |
0 |
- |
|
SCYX |
Scynexis Inc |
10% Owner |
|
2014-05-07 |
4 |
A |
$0.00 |
$0 |
D/D |
280,953 |
372,509 |
0 |
- |
|
VIRX |
Viracta Therapeutics Ord ... |
Former 10% Owner |
|
2010-06-30 |
4 |
B |
$0.28 |
$275,448 |
I/I |
1,001,628 |
268,883 |
0.01 |
- |
|
KITE |
Kite Pharma, Inc. |
Director |
|
2017-04-13 |
4 |
S |
$82.39 |
$5,954,737 |
I/I |
(72,275) |
191,144 |
0 |
- |
|
VIRX |
Viracta Therapeutics Ord ... |
10% Owner |
|
2009-04-03 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
187,714 |
|
- |
|
CORT |
Corcept Therapeutics Inc |
10% Owner |
|
2009-10-16 |
4 |
B |
$1.38 |
$17,120 |
I/I |
12,406 |
180,204 |
1.5 |
- |
|
KITE |
Kite Pharma, Inc. |
Director |
|
2017-04-17 |
4 |
S |
$82.48 |
$3,555,028 |
I/I |
(43,101) |
148,043 |
0 |
- |
|
KITE |
Kite Pharma, Inc. |
Director |
|
2017-04-24 |
4 |
S |
$82.34 |
$2,125,854 |
I/I |
(25,818) |
122,225 |
0 |
- |
|
SCYX |
Scynexis Inc |
10% Owner |
|
2014-05-07 |
4 |
OE |
$0.20 |
$18,311 |
D/D |
91,556 |
91,556 |
0 |
- |
|
KITE |
Kite Pharma, Inc. |
Director |
|
2017-04-25 |
4 |
S |
$82.56 |
$3,873,585 |
I/I |
(46,783) |
75,442 |
0 |
- |
|
KITE |
Kite Pharma, Inc. |
Director |
|
2017-06-20 |
4 |
A |
$0.00 |
$0 |
D/D |
2,410 |
66,074 |
0 |
- |
|
KITE |
Kite Pharma, Inc. |
Director |
|
2017-06-14 |
4 |
S |
$90.40 |
$1,356,000 |
D/D |
(15,000) |
63,664 |
0 |
- |
|
KITE |
Kite Pharma, Inc. |
Director |
|
2017-09-29 |
4 |
GD |
$0.00 |
$0 |
D/D |
2,800 |
63,274 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|